Protein Expression Predicts Rectal Cancer Outcomes

This article originally appeared here.
Share this content:
Protein Expression Predicts Rectal Cancer Outcomes
Protein Expression Predicts Rectal Cancer Outcomes

TUESDAY, April 4, 2017 (HealthDay News) -- Loss of E-cadherin protein expression in the pretherapeutic biopsy of rectal cancer is associated with fewer metastases and improved survival, according to a study published online March 25 in the Journal of Digestive Diseases.

Jonas Jessberger, from the Friedrich-Alexander-Universität Erlangen-Nürnberg in Germany, and colleagues evaluated 223 patients with rectal cancer treated with neoadjuvant radiochemotherapy followed by surgery. Protein expression of E-cadherin and tumor growth pattern (solid-glandular versus single-cell pattern) were assessed using 88 biopsies prior to radiochemotherapy and 213 tumor resections.

The researchers observed a significant decrease of E-cadherin expression (P = 0.002) and a significant increased single-cell growth (P = 0.001) at the invasion front in tumor samples after radiochemotherapy versus primary biopsies of the tumor. Longer metastasis-free survival (P = 0.033) and tumor-specific survival (P = 0.030) were associated with low E-cadherin expression in the biopsy. Single-cell growth at the tumor invasion front was a prognostic factor for longer tumor-specific survival (P = 0.021) after radiochemotherapy. Tumor-specific survival was independently predicted using a combination of growth pattern and the Dworak regression grade (P = 0.015).

"A combination of growth pattern and tumor regression score (RegPat-Score) showed the highest discriminatory power to identify high-risk patients," the authors writes.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »